INTRODUCTION
Inclusion body myositis (IBM), also called sporadic inclusion body myositis, is a slowly progressive muscle disease beginning in middle or later life. Tremendous unmet medical need exists for patients with IBM resulting from its relentless progression coupled with lack of effective treatment. Its unique clinical and pathologic features and poor response to medical therapy are enigmatic, challenging the medical profession to better understand the cause and mechanisms of this disease.
CLINICAL FEATURES AND DIAGNOSIS
IBM has a reported mean age of onset of between 61 and 66 years.
1Y3 Symptoms develop past the age of 40 in almost all patients and past the age of 50 in most patients ( Figure 6-1 
4
). Progression is slow; it is typically difficult to identify disease onset. Patients generally relate early symptoms to weakness of quadriceps (difficulty arising from a chair, knee buckling, falling), finger flexors (grip weakness, difficulty opening jars and manipulating objects), or swallowing. Tripping from ankle dorsiflexion weakness is a less common presenting symptom.
A preferential, but not exclusive, pattern of muscle involvement is a highly distinctive feature of IBM, involving quadriceps, finger flexors, and ankle dorsiflexors. 5, 6 The muscle involvement is asymmetric and focal, recognizable by clinical examination and MRI. Finger flexor weakness may be extremely focal, with complete paralysis of flexor digitorum profundus for one particular finger but good strength for other fingers ( Figure 6-2) . Relative preservation of flexion at the metacarpophalangeal joints and of the adductor pollicis, allowing limited grip between the thumb and second finger, is typical. Substantial quadriceps loss often goes unrecognized as it is often focal, involving vastus medialis and vastus lateralis more than rectus femoris, so that considerable medial and lateral anterior thigh atrophy may be present without substantial weakness detected by manual muscle testing. Because these muscles are often replaced with fibrous tissue, inspection may underestimate their loss ( Figure 6-3 ). It can be helpful clinically to palpate vastus medialis and vastus lateralis muscles during attempted knee extension to fully appreciate their involvement. Other commonly involved muscles are biceps brachii, triceps, and wrist flexors, while perhaps the least or latest affected muscles are hip adductors, neck extensors, and lumbricals. Facial weakness is common and underrecognized.
Diagnostic studies that may be abnormal in IBM are limited. Needle EMG typically shows fibrillation potentials and positive sharp waves. However, motor units can be large, suggesting a neurogenic process. Examination of flexor digitorum profundus, especially for the fourth and fifth fingers, can be very helpful. Serum creatine kinase is typically modestly elevated (less than five times the upper limit of normal); marked elevations (eg, more than 10 times the upper limit of normal) should suggest another diagnosis or a coexisting cause (eg, IBM and statin toxicity). MRI can be helpful in identifying muscle involvement, but generally this is clinically obvious. Biopsies of involved muscles demonstrate a profound inflammatory response as well as characteristic rimmed vacuoles. However, because rimmed vacuoles may have a patchy distribution, they are not always seen, even when the rest of the clinical presentation is characteristic of IBM. The identification of a serum autoantibody against NT5C1A has enabled blood testing for IBM 7Y10 and may obviate the need for muscle biopsy in some patients.
IBM diagnosis is frequently delayed, and misdiagnosis is common. The mean time to correct diagnosis after onset of symptoms has been estimated at 5.2 to 5.6 years. 3, 11 Many patients are initially diagnosed with polymyositis and then refractory polymyositis. Underreliance on simple physical examination to identify features suggestive of IBM (eg, identifying finger flexor weakness or side-to-side asymmetry) and overreliance on muscle biopsy pathology (eg, absence of rimmed vacuoles) account for most diagnostic errors (Case 6-1). Some cases are mistaken for amyotrophic lateral sclerosis because of the EMG findings (fibrillations, positive sharp waves, large motor units). Careful clinical examination demonstrating finger flexor weakness with preservation of intrinsic hand muscle strength should avoid this misdiagnosis.
The clinical diagnosis of IBM is not challenging if finger flexor muscles are involved and are examined. Subtle weakness that may be patchy, particularly in flexor digitorum profundi, is commonly overlooked. This clinical presentation is so suggestive of the disease in most patients that additional diagnostic tests are useful primarily to exclude unsuspected h The identification of a serum autoantibody against NT5C1A has enabled blood testing for inclusion body myositis. The development of a blood biomarker with high specificity for IBM among muscle diseases has been a significant advance in the field (refer to the section on disease mechanisms later in this article). Anti-NT5C1A antibodies have been reported present in 37% to 76% of patients with IBM (Table 6-1).
7Y10,12Y14
The sensitivity of the test is highly dependent on the methodology and thresholds used. Among patients with muscle diseases, the reported specificities have ranged from 87% to 100%. Although its clinical value is still being defined, the high specificity of the test indicates that when positive in a patient with a typical clinical phenotype, muscle biopsy may not be necessary. 1987 and in publications of consensus expert opinions from five meetings between 1995 and 2011. 15 Generally, these publications have described features (eg, presence of quadriceps weakness), categories (combinations of features), and schemes (combinations of categories; eg, definite, probable, and possible). These consensus features, categories, and schemes were driven by expert consensus but published in the absence of data on their sensitivity and specificity for IBM among muscle diseases.
RESEARCH DIAGNOSTIC CRITERIA
The most recent criteria are those from a 2011 consensus meeting of the European Neuromuscular Centre, 16 but perhaps the best systems are the 2000 European Neuromuscular Centre criteria 17 and the simple 2014 data-derived criteria tested on 371 patients, with a sensitivity of 90% and specificity of 96%. 15 These data-derived criteria are finger flexor or quadriceps weakness, endomysial inflammation, and either invasion of non-necrotic muscle fibers or rimmed vacuoles.
HISTORY AND TERMINOLOGY
IBM is classified as one of the inflammatory myopathies, a category that also includes dermatomyositis, polymyositis, and immune-mediated necrotizing myopathy.
Case 6-1
A 67-year-old man presented with a 1-year history of progressive weakness of left hand grip and 6 months of weakness of right hand grip. Neurologic examination showed mild weakness of bilateral elbow flexors and wrist flexors, left worse than right; focal patchy weakness of finger flexors, especially deep finger flexors, ranging from moderate to severe; mild weakness of hip flexors and knee extensors; and moderate weakness of ankle dorsiflexors. Nerve conduction studies were normal, and needle EMG showed fibrillation potentials and early recruitment of motor units, especially in flexor digitorum profundus to the fourth and fifth fingers. Serum creatine kinase was modestly elevated (489 IU/L, with the upper limit of normal being 320 IU/L). Muscle biopsy showed endomysial inflammation and invasion of non-necrotic muscle fibers by inflammatory cells, but no rimmed vacuoles. A 6-month trial of prednisone and a 3-month trial of IV immunoglobulin (IVIg) showed no benefit. Repeat muscle biopsy showed the same findings. Serum blood testing showed autoantibodies against NT5C1A.
Comment. This patient presented with typical clinical findings of inclusion body myositis. The combination of pronounced finger flexor involvement and endomysial inflammation on muscle biopsy is highly specific to inclusion body myositis and is sufficient for diagnosis. The lack of rimmed vacuoles often leads to a diagnosis of polymyositis and treatment with corticosteroids or IVIg. Whether or not rimmed vacuoles are present in this setting does not alter the refractoriness of patients with this presentation to these treatments. 21 IBM is frequently confused with another class of disorders, the hereditary inclusion body myopathies often abbreviated h-IBM. 22 These disorders bear little clinical resemblance to IBM. Some authors have taken to calling IBM sporadic inclusion body myositis, abbreviated s-IBM to distinguish it from these other hereditary disorders. However, the M in IBM stands for ''myositis'' not myopathy, and, accordingly, the term h-IBM is inappropriate. More correctly, these hereditary disorders fall within the category of rimmed-vacuole myopathies, which includes a number of genetic disorders (eg, myofibrillar myopathies, myopathy due to valosin-containing protein mutations, oculopharyngeal muscular dystrophy, Welander distal myopathy) as well as IBM. IBM maintains a dual status as both an inflammatory myopathy and a rimmed-vacuole myopathy. 27 Using the highest published prevalence rate, it is estimated that 23,000 people are affected in the United States and 72,000 people are affected in the United States, European Union, Canada, Australia, and Japan combined.
EPIDEMIOLOGY
Evidence for a truly increasing prevalence of the disease in Japan has been suggested by muscle pathologyYbased diagnosis of archived materials, with an ) ( Figure 6-6 ); tubulofilaments and cytomembranous whorls visible by electron microscopy ( Figure 6-7) ; and sarcoplasmic aggregation and deposition of various proteins, including transactive response DNAbinding protein 43 (TDP-43) 30,31 and p62 32 seen by immunohistochemistry (Figure 6-8) .
Mitochondrial abnormalities have also been emphasized. Some patients lack the degenerative feature of rimmed vacuoles, but nevertheless have clinical features of IBM and have failed to respond to standard immunotherapies. 33 IBM came from its study under the microscope. Immunohistochemical techniques applied in the 1980s 34Y36 supplemented gross microscopy, creating a biased ability to see specific proteins, but only those that were specifically targeted for visualization. The application of unbiased genomic technologies to IBM muscle demonstrated a rich molecular pathology not visible to the eye. 37, 38 IBM muscle contains highly overproduced gene transcripts for numerous immune system soluble proteins, such as the cytokine tumor necrosis factor beta (TNF-"), as well as potent chemokines that attract and activate cells of the immune system.
MOLECULAR PATHOLOGY

DISEASE MECHANISMS
The mechanisms resulting in muscle damage in IBM are incompletely understood. In support of the autoimmune hypothesis, a universal feature of IBM is microscopically visible destruction of non-necrotic muscle fibers by cytotoxic T cells; indeed, the presence of invading T cells is a required criterion for IBM diagnosis in all expert consensusYbased classification schemes. 15 However, myonuclear degeneration and the redistribution of myonuclear nucleic acidYbinding proteins into IBM sarcoplasm are also impressive features. 31 There exists a long history of IBM pathogenic theories (Table 6-3) . Early speculations of viral infection have remained unproven. Mitochondrial dysfunction and mutations may play a role. However, such changes are correlated with and may be a consequence of inflammation in IBM muscle 39 as similar changes are seen in target tissues in other inflammatory diseases such as rheumatoid arthritis. 40 The view that IBM is caused by amyloid-" accumulation dominated the field for perhaps 20 years and has still been advocated in recent publications. Initial recognition of myonuclear degeneration giving rise to rimmed vacuoles, 21,41Y43 which is currently believed to be true, 29 was previously abandoned by most authors in favor of a theory of molecular toxicity due to amyloid-" peptide. 44 The claim that amyloid-" precursor protein (APP) gene expression is elevated in IBM, the basis for human and animal models of the disease, was first published in 1993 45 and then supplemented in a 1994 publication 46 by the same authors, who found it to be simply a marker of regenerating myofibers increased in all muscle diseases studied, including polymyositis, dermatomyositis, amyotrophic lateral sclerosis, and Duchenne muscular dystrophy. Analysis of a citation network in 2009 47 noted that the 1993 publication had received 54 citations in support of the idea of APP-mediated injury in IBM, while the 1994 publication, pointing out APP nonspecificity as a marker of regenerating myofibers, received only four citations. Quantitative studies of APP transcript abundance in muscle by microarrays 37 and polymerase chain reaction (PCR) 48 were first performed a decade later and found no differences among inflammatory myopathies or even higher abundance in dermatomyositis than in IBM muscle. 
Immunologic Mechanisms
Many experts have argued that IBM is not an autoimmune disease because it does not respond to standard immunotherapies. In the author's opinion, this view is limited, as many patients with autoimmune diseases are refractory to standard and more advanced therapies. The immune-mediated mechanisms present in IBM muscle are impressive and, by any measure of degree, exceed the autoimmunity present in any other muscle disease. These involve cytotoxic T cells; B cells, plasma cells, and the antibodies they secrete 7Y10,28,37,49,50 ; macrophages and myeloid dendritic cells 51 ; and various soluble molecules produced by myofibers and immune cells.
Effector cytotoxic CD8+ T cells invading myofibers have been emphasized since their identification in 1984 as the most prominent aspect of autoimmunity within IBM muscle visible by microscopy. 34Y36 These cells directly injure
FIGURE 6-7
Cytomembranous whorls and tubulofilaments in inclusion body myositis. AYG, Normal-appearing myonuclei (white arrowheads) are intermixed with cytomembranous whorls (black arrowheads) and pale segmented structures that have the morphology of nuclei but have diminished nucleoplasmic staining (F, G, gray arrowheads). G, A vacuole is more than 100 2m in length and contains many of these structures that appear to be nuclei devoid of nucleoplasm. H-1, H-2, I-1, and I-2, Nuclear tubulofilaments (black arrows) seen by electron microscopy. Scale bar = 20 2m. otherwise healthy-appearing myofibers ( Figure 6-9) . Since their identification, injury of IBM muscle has largely been viewed as T-cell mediated. These cytotoxic T cells are clonally expanded in blood and muscle, 52Y55 likely in response to antigen stimulation. A link between IBM and a neoplastic disease of CD8+CD57+ T cells, T-cell large granular lymphocytic leukemia, has been suggested by case reports. 56 Most patients with IBM have expansions of CD8+CD57+ large granular lymphocytes that can be detected in blood by T-cell counts and flow cytometry and are infiltrating muscle. 57 Although B cells were thought to play no role in IBM based on 1984 immunohistochemical studies, 34 the use of genomic technologies 2 decades ago 37 identified robust B-cell activation in IBM muscle, including CD138+ plasma cells that are clonally expanded and antigen-directed 49, 50 ( Figure 6-10 
58
). These studies led to identification of a serum autoantibody present against cytoplasmic 5 ¶ nucleotidase (NT5C1A; cN1A), now widely confirmed by multiple independent laboratories. 7Y10,12Y14 NT5C1A is the first autoantigen biomarker discovered for IBM, and its identification adds further support to the theory that IBM is an autoimmune disease.
Degenerative Mechanisms
Various structural abnormalities visible by microscopy with routine histologic and special immunohistochemical methods have been categorized as degenerative mechanisms in IBM muscle. Rimmed vacuoles, inclusion bodies, and cytomembranous whorls ( Figure 6-6 and Figure 6 -7) are of this nature, as are various aggregated proteins, only a fraction of which appear to be ''amyloid'' (Congo redYpositive material). Myonuclear degeneration gives rise to rimmed vacuoles and displacement of normally nuclear nucleic acidYbinding proteins into sarcoplasm. 29Y31 A potential link between autoimmunity and myonuclear degeneration was suggested by a yet unconfirmed observation that NT5C1A accumulates in and around rimmed vacuoles. 8 
KEY POINTS
h The immune-mediated mechanisms present in inclusion body myositis muscle are impressive and, by any measure of degree, exceed the autoimmunity present in any other muscle disease.
h A link between inclusion body myositis and a neoplastic disease of CD+CD57+ T cells, T-cell large granular lymphocytic leukemia, has been suggested by case reports. Two pharmacologic therapeutic approaches, counteracting atrophy through muscle building and modulating T cells, have shown hints of potential efficacy. One of these placebo-controlled clinical trials statistically achieved its prespecified primary outcome measure (increase in thigh muscle volume). This was a small single-dose placebo-controlled trial of bimagrumab, a monoclonal antibody against an activin receptor. Blockade of this receptor can potentially block the atrophying effects that follow phosphorylation of SMAD2/SMAD3, detected in IBM muscle in pretrial translational studies. 59 A subsequent 240 person phase 2b/3 clinical trial did not meet its predefined primary outcome measure of improved 6-minute walk distance. 60 However, in unpublished preliminary analysis, this second study did show dose-related statistically significant increases in muscle mass as measured by dual-energy x-ray absorptiometry (DEXA). A study of oxandrolone, an anabolic steroid that also builds muscle, nearly achieved statistical significance (P=.06) in another trial. 61 An overlying concept, to build muscle, is present for both of these therapeutic approaches.
Modulation of T cells has been attempted in an unblinded study with antiYT-lymphocyte globulin (ATG) and an unblinded and uncontrolled study with alemtuzumab, an anti-CD52 monoclonal antibody. Both agents lack specificity for T cells and target and can deplete multiple other immune cell types (eg, CD52 is expressed on T and B lymphocytes, monocytes, macrophages, and dendritic cells). The ATG study 62 lymphapheresis, lack of comparatortreated control group, and other methodologic issues. 64 A study of rapamycin is aimed at modulating effector T cells; the known muscle atrophyYinducing effects of this drug 65, 66 are a concern for IBM. CONCLUSION IBM has tremendous unmet medical need. It is a challenging disease to secure research funding for and to understand. Its prevalence is underestimated and likely increasing. The identification of a B-cell pathway has resulted in the first identifi- cation of an IBM autoantigen and emphasized its status as an autoimmune disease. The recognition that large granular lymphocyte CD8+ T-cell expansions are present in both blood and muscle provides additional biomarkers for IBM and suggests a mechanistic relationship to the neoplastic disease T-cell large granular lymphocytic leukemia. 
KEY POINT
h The identification of a B-cell pathway has resulted in the first identification of an inclusion body myositis autoantigen and emphasized its status as an autoimmune disease.
